<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4"><strong>HSV in Pregnancy and Neonate </strong></h1><h2 class="text-xl font-semibold mt-6 mb-3">2024 BASHH/RCOG Guideline Summary<strong>Maternal Management</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>General Principles</strong></h3><ul><li>Antenatal counselling about HSV for all mothers.</li><li>Confirm diagnosis with PCR (ulcer panel: HSV, VZV, syphilis ± others by risk).</li><li>Refer to GUM/virology; delivery plan documented with MDT (GUM, obstetrics, neonatology).</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>First Episode HSV</strong></h3><ul><li><strong>Treatment:</strong><ul><li>Oral aciclovir 400 mg TDS × 5 days OR valaciclovir 500 mg BD × 5 days.</li><li>IV aciclovir (10 mg/kg TDS) if disseminated/severe.</li></ul></li><li><strong>Suppressive therapy:</strong><ul><li>Start at <strong>32 weeks</strong> (aciclovir 400 mg TDS or valaciclovir 500 mg BD).</li><li>If high risk preterm → start at <strong>22 weeks</strong> (aciclovir 400 mg BD or valaciclovir 500 mg OD until 32 weeks, then escalate).</li></ul></li><li><strong>Mode of delivery:</strong><ul><li>1st/2nd trimester infection, delivery &gt;6 weeks later → vaginal delivery.</li><li>Delivery within 6 weeks of primary infection → Caesarean.</li></ul></li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Recurrent HSV</strong></h3><ul><li>Transmission risk low (0–3%).</li><li>Vaginal delivery unless obstetric reason for Caesarean.</li><li>Suppressive therapy as above.</li><li>Episodic recurrences: oral aciclovir/valaciclovir.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>At Onset of Labour</strong></h3><ul><li><strong>Primary/non-primary lesions:</strong><ul><li>Caesarean recommended (&lt;4 h ROM optimal).</li><li>If vaginal delivery (maternal choice/prolonged ROM) → IV aciclovir intrapartum (5 mg/kg q8h) and treat neonate.</li></ul></li><li><strong>Recurrent lesions:</strong> Vaginal delivery acceptable; Caesarean not routinely indicated.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Special Situations</strong></h3><ul><li><strong>PPROM (&lt;37 weeks):</strong><ul><li>Primary HSV → manage as <em>highest neonatal risk</em>, IV aciclovir until delivery, MDT discussion.</li><li>Recurrent HSV → expectant management &lt;34 weeks, antivirals until delivery; follow RCOG PPROM guidance.</li></ul></li><li><strong>HIV co-infection:</strong> Manage as HIV-negative; align with BHIVA HIV-in-pregnancy guidance.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>Neonatal Management</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Risk-Stratified Investigations</strong></h3><h4 class="text-base font-semibold mt-4 mb-2"><strong>Highest Risk</strong></h4><ul><li><strong>Who:</strong> <ul><li>Symptomatic infants; </li><li>any positive neonatal HSV test; </li><li>vaginal birth with maternal first initial primary/non-primary lesions; </li><li>maternal systemic HSV illness; </li><li>maternal primary HSV up to 4 weeks postpartum.</li></ul></li><li><strong>Timing:</strong> Immediate/urgent (don’t wait to 24 h).</li><li><strong>Samples:</strong><ul><li>Surface swabs: any lesions + throat, nose, conjunctivae, rectum.</li><li>Blood: EDTA HSV PCR, FBC, LFTs, coagulation.</li><li>CSF (if safe): HSV PCR, protein, glucose, cell count/microscopy/culture.</li><li>Other tests as clinically indicated; consider resistance testing.</li></ul></li><li><strong>Management:</strong> Start IV aciclovir 20 mg/kg q8h immediately.<ul><li>10 days if all negative</li><li>14 days if skin/mouth/eyes</li><li>21 days for CNS</li></ul></li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>High Risk</strong></h4><ul><li><strong>Who:</strong> <ul><li>Asymptomatic infants with maternal infection within 6 weeks.</li></ul></li><li><strong>Timing:</strong> At ≥24 h of life (repeat if earlier).</li><li><strong>Samples:</strong><ul><li>Surface swabs: throat, nose, conjunctivae, rectum.</li><li>Blood: EDTA HSV PCR, FBC, LFTs, coagulation.</li><li>CSF (if safe): HSV PCR, protein, glucose, cell count/microscopy/culture.</li></ul></li><li>Management:<ul><li>Start IV aciclovir 20 mg/kg q8h immediately.</li><li>10 days if all negative or if positive from unbroken skin only</li></ul></li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>Low Risk</strong></h4><ul><li><strong>Who:</strong> Asymptomatic infants with maternal recurrent lesions at delivery, or remote (&gt;6 weeks) HSV history but no active lesions.</li><li><strong>Timing:</strong> At ≥24 h of life.</li><li><strong>Samples:</strong><ul><li>Surface swabs: throat, nose, conjunctivae, rectum.</li><li>Blood: EDTA HSV PCR, FBC, LFTs, coagulation.</li><li>CSF if clinically indicated / escalate if positive or symptomatic.</li></ul></li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>Lowest Risk</strong></h4><ul><li><strong>Who:</strong> Term, asymptomatic, no active lesions at delivery, maternal HSV history &gt;6 weeks previously.</li><li><strong>Investigations:</strong> None. Routine newborn care with standard postnatal exam and safety-netting.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Duration of Therapy (if treated)</strong></h3><ul><li>SEM disease: 14 days IV aciclovir.</li><li>CNS/disseminated: 21 days IV aciclovir (ensure negative CSF before stopping).</li><li>All-negative but treated empirically: 10 days IV aciclovir.</li><li>Follow with 6 months oral aciclovir prophylaxis if CNS/disseminated; consider in SEM.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>Prevention of Postnatal Transmission</strong></h2><ul><li>Parents: hand hygiene, no kissing near face, avoid if cold sores/whitlows.</li><li>Staff with lesions: liaise with Occupational Health, cover lesions, hand hygiene, consider suppression.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>Breastfeeding</strong></h2><ul><li>Aciclovir/valaciclovir safe (&lt;1% infant dose in milk).</li><li>Do <strong>not</strong> feed from breast with active herpetic lesions; discard expressed milk from affected side until healed.</li><li>Cover lesions, sterilise equipment.</li><li>Consider suppression (aciclovir/valaciclovir) after breast HSV until 6 months postpartum.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>Discordant Couples</strong></h2><ul><li>Pregnant person seronegative, partner HSV-positive = high risk.</li><li>Abstain from sex (including oral) in 3rd trimester (and 2 weeks before).</li><li>If not abstinent: use condoms, partner suppression therapy.</li><li>Avoid receptive oral sex in late pregnancy if partner has oral HSV.</li></ul><p><strong>Key Point:</strong> Any positive infant HSV test or clinical suspicion = treat as <em>highest risk</em> with immediate IV aciclovir and full investigations.</p>
</div>